Latest News

  • UK Consortium Builds Cancer Dataset and AI Models with 10x Xenium Spatial Platform

    Diagnostics World News | PharosAI, a research consortium of four UK institutions, plans to use the 10x Genomics Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets and pair them with advanced AI models and analytical capabilities. They plan to democratize access to these datasets, ensuring they are securely available to a broad community of researchers and innovators.

    Feb 6, 2026

  • Parkinson’s Disease Can Now Be Identified in Blood

    Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.

    Feb 5, 2026

  • Parkinson’s Disease Can Now Be Identified in Blood

    Diagnostics World News | No cure or established early-stage detection method for Parkinson's disease has been found yet. Patients do not receive a diagnosis until motor symptoms begin to appear. A team of researchers from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway have found a way to identify early signs of Parkinson’s disease in the blood.

    Feb 5, 2026

  • Study Suggests ‘Brain is to Blame’ for High Blood Pressure

    Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.

    Feb 3, 2026

  • Follow the Money: Cell Stress Sensing Platform, Next-Gen Precision Diagnostics Platform, Novel Proximity-Modulating Therapeutics

    Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.

    Jan 28, 2026

  • Autism Early Risk Identifier, Increased Demand for Molecular Testing, Collaboration for Colorectal Cancer Detection

    Diagnostics World News | NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth; Cytespace expanded its molecular testing to meet increasing demands across Sub-Saharan Africa; Daisy Genomics and New Day Diagnostics have entered a collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance; and more.

    Jan 27, 2026

  • Autism Early Risk Identifier, Increased Demand for Molecular Testing, Collaboration for Colorectal Cancer Detection

    Diagnostics World News | NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth; Cytespace expanded its molecular testing to meet increasing demands across Sub-Saharan Africa; Daisy Genomics and New Day Diagnostics have entered a collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance; and more.

    Jan 27, 2026

  • Quest is on for Meaningful Outcome Measures for Anti-Obesity Drugs

    Diagnostics World News | A lot is at stake in obesity drug development, heightening the focus of pharma sponsors on producing the right evidence to support a label claim and differentiating their products in the rapidly growing weight management pharmacotherapy market. It’s also the rationale for the industrywide DECODE Obesity initiative of Ametris (formerly ActiGraph) looking to expand the range of outcome measures beyond weight loss.

    Jan 23, 2026